The somatic genomic landscape of glioblastoma.

The somatic genomic landscape of glioblastoma.
复制标题

DOI:
10.1016/j.cell.2013.09.034
复制
发表时间:
2013-10-10
期刊:
影响因子:
64.5
通讯作者:
TCGA Research Network
TCGA Research Network
中科院分区:
生物学1区
文献类型:
--
作者:
Brennan CW;Verhaak RG;McKenna A;Campos B;Noushmehr H;Salama SR;Zheng S;Chakravarty D;Sanborn JZ;Berman SH;Beroukhim R;Bernard B;Wu CJ;Genovese G;Shmulevich I;Barnholtz-Sloan J;Zou L;Vegesna R;Shukla SA;Ciriello G;Yung WK;Zhang W;Sougnez C;Mikkelsen T;Aldape K;Bigner DD;Van Meir EG;Prados M;Sloan A;Black KL;Eschbacher J;Finocchiaro G;Friedman W;Andrews DW;Guha A;Iacocca M;O'Neill BP;Foltz G;Myers J;Weisenberger DJ;Penny R;Kucherlapati R;Perou CM;Hayes DN;Gibbs R;Marra M;Mills GB;Lander E;Spellman P;Wilson R;Sander C;Weinstein J;Meyerson M;Gabriel S;Laird PW;Haussler D;Getz G;Chin L;TCGA Research Network

文献摘要

参考文献

被引文献

相似文献

我们根据 500 多种胶质母细胞瘤 (GBM) 的多维和综合特征描述了体细胞基因组改变的情况。我们鉴定了几个新的突变基因以及特征受体(包括 EGFR 和 PDGFRA)的复杂重排。 TERT 启动子突变被证明与 mRNA 表达升高相关,支持端粒酶重新激活中的作用。相关分析证实,原神经亚型的生存优势是由 G-CIMP 表型赋予的,并且 MGMT DNA 甲基化可能是仅在经典亚型 GBM 中治疗反应的预测生物标志物。基因组和蛋白质组谱的综合分析挑战了治疗性抑制途径作为抑制靶标本身的替代方案的概念。这些数据将有助于发现候选治疗和诊断目标、验证研究和临床观察以及产生意想不到的假设,从而促进我们对这种致命癌症的分子理解。
We describe the landscape of somatic genomic alterations based on multi-dimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature receptors including EGFR and PDGFRA. TERT promoter mutations are shown to correlate with elevated mRNA expression, supporting a role in telomerase reactivation. Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM. Integrative analysis of genomic and proteomic profiles challenges the notion of therapeutic inhibition of a pathway as an alternative to inhibition of the target itself. These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations and the generation of unanticipated hypotheses that can advance our molecular understanding of this lethal cancer.
DOI: 10.1101/gad.1890510
发表时间: 2010-08-15
影响因子: 10.5
作者:
Inda, Maria-del-Mar;Bonavia, Rudy;Furnari, Frank
通讯作者: Furnari, Frank
DOI: 10.1371/journal.pone.0007752
发表时间: 2009-11-13
期刊: PloS one
影响因子: 3.7
作者:
Brennan C;Momota H;Hambardzumyan D;Ozawa T;Tandon A;Pedraza A;Holland E
通讯作者: Holland E
DOI: 10.1038/nature08822
发表时间: 2010-02-18
期刊: Nature
影响因子: 64.8
作者:
通讯作者: --
DOI: 10.1158/0008-5472.can-11-0821
发表时间: 2011-12-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Cho, Jeonghee;Pastorino, Sandra;Meyerson, Matthew
通讯作者: Meyerson, Matthew
DOI: 10.1093/neuonc/nos218
发表时间: 2012-11-01
期刊: NEURO-ONCOLOGY
影响因子: 15.9
作者:
Dolecek, Therese A.;Propp, Jennifer M.;Kruchko, Carol
通讯作者: Kruchko, Carol